GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cambridge Nutritional Sciences CNSL.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

1.55p

0.00%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cambridge Nutritional Sciences

Its shares trade on LSE under the ticker CNSL.L. It has been listed since 18 March 2004. In the fiscal year to 31 March 2026, it reported revenue of £7.0m and a net loss of £5.8m. At that date it held total assets of £7.4m and shareholders' equity of £5.7m.

Omega Diagnostics Group Plc is a holding company, which engages in the manufacture, development, and distribution of medical diagnostics products. The company is headquartered in Alva, Stirlingshire. The company went IPO on 2004-03-18. The firm's segments are Allergy and Autoimmune; Food Intolerance; Infectious/Other, and Corporate. Its product categories include allergy, anemia, autoimmunity, fertility and growth hormones, food intolerance, infectious disease, inflammation, quality control, thyroid hormones and tumor markers. For allergy, it offers Allergodip, which is an enzyme immunoassay for the semi-quantitative determination of Specific immunoglobulin E (IgE) in serum or plasma. For anemia, it offers ATHOZYME Ferritin, which is an enzyme-immunoassay (ELISA) test for the detection and quantification of Ferritin in human serum. The company offers a range of products for Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Antiphospholipid Syndrome (APS), Connective Tissue Disease, Gastrointestinal, and Vasculitis and Renal Disease. Its Fertility Hormones products include PATHOZYME-LH (Luteinizing Hormone), PATHOZYME-Prolactin and PATHOZYME-Oestradiol.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
18 Mar 2004
Employees
152

Leadership

Pay as last reported

  • Ms. Carolyn RandNon-Executive Independent Chairman of the Board£117,000
  • Mr. James CooperChief Executive Officer, Executive Director, since 2024£160,000
  • Mr. Ajay PatelChief Financial Officer, Executive Director, since 2025
  • Mr. Jeremy MillardNon-Executive Independent Director£38,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.